News

FDA posts briefing materials prior to Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart (6 November 2012)

Read the full announcement in PDF format

Bagsværd, Denmark, 6 November 2012 Novo Nordisk announced today that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the New Drug Applications (NDA) for insulin degludec and insulin degludec/insulin aspart, which will take place on 8 November 2012.

The briefing documents from Novo Nordisk and the FDA, which will form the basis for the Advisory Committee's discussion, provide an overview of the non-clinical and clinical data for insulin degludec and insulin degludec/insulin aspart for the treatment of diabetes.

The briefing materials can be accessed on the FDA webpage here

Further information

Media:
Mike Rulis +45 3079 3573 mike@novonordisk.com
Ambre Morley (US) +1 609 216 5240 abmo@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 4442 4303 krop@novonordisk.com
Frank Daniel Mersebach +45 4442 0604 fdni@novonordisk.com
Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com
Jannick Lindegaard (US) +1 609 786 4575 jlis@novonordisk.com

Company Announcement no. 71 2012

 

 

 

 

  •  
Search for Danish versions and earlier news releases:

Language
Year
Month
Type
Search for:

Search
  •  
  •  

Sign up for the latest news from Novo Nordisk

SMS/e-mail

Twitter

Facebook

RSS feeds

 
  •  
  •  
Pipeline
  •  
  •  
Click here to go to the download centre to download presenations, reports or magazines
  •